Anti-GTPase HRAS antibody (ab96548)


  • Product nameAnti-GTPase HRAS antibody
    See all GTPase HRAS primary antibodies
  • Description
    Rabbit polyclonal to GTPase HRAS
  • Tested applicationsSuitable for: WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide conjugated to KLH derived from within residues 100 to the C-terminus of Human GTPase HRAS.

  • Positive control
    • This antibody gave a positive signal in the following whole cell lysates: PC12; HeLa. IF/ICC: HeLa cell line.


Associated products


Our Abpromise guarantee covers the use of ab96548 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Detects a band of approximately 21 kDa (predicted molecular weight: 21 kDa).
ICC/IF Use at an assay dependent concentration.


  • FunctionRas proteins bind GDP/GTP and possess intrinsic GTPase activity.
  • Involvement in diseaseDefects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
    Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
    Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
    Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
    Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
    Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
  • Sequence similaritiesBelongs to the small GTPase superfamily. Ras family.
  • Post-translational
    Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
    S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
  • Cellular localizationCell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
  • Information by UniProt
  • Database links
  • Alternative names
    • C BAS/HAS antibody
    • c H ras antibody
    • C HA RAS1 antibody
    • c has/bas p21 protein antibody
    • c ras Ki 2 activated oncogene antibody
    • c-H-ras antibody
    • CTLO antibody
    • GTP and GDP binding peptide B antibody
    • GTPase HRas, N-terminally processed antibody
    • H Ras 1 antibody
    • H RASIDX antibody
    • H-Ras-1 antibody
    • Ha Ras antibody
    • Ha Ras1 proto oncoprotein antibody
    • Ha-Ras antibody
    • HAMSV antibody
    • Harvey rat sarcoma viral oncogene homolog antibody
    • Harvey rat sarcoma viral oncoprotein antibody
    • HRAS antibody
    • HRAS1 antibody
    • K ras antibody
    • N ras antibody
    • p19 H RasIDX protein antibody
    • p21ras antibody
    • Ras family small GTP binding protein H Ras antibody
    • RASH_HUMAN antibody
    • RASH1 antibody
    • Transformation gene oncogene HAMSV antibody
    • Transforming protein p21 antibody
    • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
    • VH Ras antibody
    • vHa RAS antibody
    see all

Anti-GTPase HRAS antibody images

  • ICC/IF image of ab96548 stained HeLa cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab96548, 10µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG(H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • All lanes : Anti-GTPase HRAS antibody (ab96548) at 1 µg/ml

    Lane 1 : PC12 (Rat adrenal pheochromocytoma cell line) Whole Cell Lysate at 10 µg
    Lane 2 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg/ml

    Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
    developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 21 kDa
    Observed band size : 21 kDa
    Additional bands at : 125 kDa,80 kDa. We are unsure as to the identity of these extra bands.

    Exposure time : 12 minutes

  • developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 21 kDa

    Exposure time : 10 seconds

References for Anti-GTPase HRAS antibody (ab96548)

ab96548 has not yet been referenced specifically in any publications.

Product Wall

Thank you for contacting us.
ab97488 and ab6548 are alternative to sc-520. Please note this assumption is based on the location of immunogen only. We might not have similar species or application data.
ab140962 and ab140377 are expected alter...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Mouse Tissue lysate - whole (skin)
Loading amount 30 µg
Specification skin
Gel Running Conditions Reduced Denaturing (15%)
Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 5% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Feb 22 2012

Thank you for your reply. I have created the discount code below, which can be redeemed for a free primary antibody after submitting a review of ab96548 and following the instructions below. Please let me know if you have any questions or if there is a...

Read More

Thank you for contacting us with your enquiry.
I have run some alignments between the immunogens of ab64705 and ab96548, and ab96548 is more specific for HRas. The immunogen of ab64705 overlaps quite a bit with N and KRas, however ab96548 shows no...

Read More